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Intracerebral infection of susceptible mouse strains with Theiler's murine encephalomyelitis virus (TMEV) results in an immune-mediated
demyelinating disease similar to human multiple sclerosis. TMEV infection is widely spread via fecal–oral routes among wild mouse populations,
yet these infected mice rarely develop clinical disease. Oral vaccination has often been used to protect the host against many different infectious
agents, although the underlying protective mechanism of prior oral exposure is still unknown. To understand the mechanisms involved in
protection from demyelinating disease following previous oral infection, immune parameters and disease progression of mice perorally infected
with TMEV were compared with those of mice immunized intraperitoneally following intracerebral infection. Mice infected perorally, but not
intraperitoneally, prior to CNS viral infection showed lower chronic viral persistence in the CNS and reduced TMEV-induced demyelinating
disease. However, a prolonged period of post-oral infection was necessary for effective protection. Mice orally pre-exposed to the virus displayed
markedly elevated levels of antibody response to TMEV in the serum, although T cell responses to TMEV in the periphery were not significantly
different between perorally and intraperitoneally immunized mice. In addition, orally vaccinated mice showed higher levels of early CNS-
infiltration of B cells producing anti-TMEV antibody as well as virus-specific CD4+ and CD8+ T cells in the CNS compared to intraperitoneally
immunized mice. Therefore, the generation of a sufficient level of protective immune responses appears to require a prolonged time period to
confer protection from TMEV-induced demyelinating disease.
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Once pathogens gain access to the CNS, infection often
results in deadly consequences due to the unique nature of the
site, as no immune cells are readily available. Thus, effective
means to vaccinate against CNS pathogens such as West Nile
virus and Japanese encephalomyelitis virus could be very
helpful. The oral route has been used to vaccinate against a
variety of viral infections (Cox et al., 2004; Fekadu et al., 1996;Abbreviations: MS, Multiple sclerosis; TMEV, Theiler's murine encepha-
lomyelitis virus; TMEV-IDD, TMEV-induced demyelinating disease; CNS,
central nervous system.
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doi:10.1016/j.virol.2007.04.017Foxwell et al., 2006; Ramakrishna et al., 1999; Vesikari et al.,
2006; Zhao et al., 2006). In particular, vaccination against
poliovirus is a remarkably successful example (Sabin, 1985).
However, very little is known about the immunological mecha-
nisms involved in the efficacy of oral vaccination. Despite the
extensive use of oral vaccination against many viral infections,
very few systemic studies have examined the time and type of
immune responses required for effective protection. Although
intracerebral infection of Theiler's murine encephalomyelitis
virus (TMEV) consistently induces demyelinating disease in
susceptible mice (Lipton, 1975), infection via other routes
seldom induces demyelinating disease (Thompson et al., 1951).
The wild mouse population is widely infected with TMEV,
presumably via the fecal–oral route, without apparent disease
(Lipton et al., 2001). Similarly, human populations have been
exposed to many different viruses without apparent clinical
Fig. 1. Requirement of greater than 45 days after oral immunization for effective
protection from TMEV-IDD. Female SJL/J mice were orally immunized with
1×107 PFU TMEV BeAn at 30 (n=10), 45 (n=10), or 51 (n=6) days prior to
intracerebral infection with 1×106 PFU TMEV. All mouse groups were
intracerebrally infected with TMEVon the same day at 15 weeks of age. Peroral
(PO) immunization resulted in significantly lower incidence of TMEV-IDD
compared to those non-immunized. Mice immunized at 45 days or earlier (51
days) prior to intracerebral (ic) infection were effectively protected, but mice
immunized at 30 days prior to infection were not. Differences in disease
incidences between the non-immunized group and the orally immunized group
are as follows, based on a paired, two-tailed Student's t-test with Welch
correction between 28 and 56 days post-infection: at −30 days, pN0.05 (not
significant); −45 days, pb0.01 (very significant); and −51 days, pb0.01 (very
significant).
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whether mice pre-exposed to the virus become resistant to
developing demyelinating disease, and if they do, what are the
immunological mechanisms of acquired resistance to TMEV-
induced CNS disease.
TMEV belongs to the Picornavirus family. Intracerebral (ic)
inoculation of susceptible mice with the BeAn 8386 or DA
strains of TMEV results in a chronic progressive demyelinating
disease in the CNS (Lipton, 1975). There are strong similarities
between TMEV-induced demyelinating disease (TMEV-IDD)
and human multiple sclerosis (MS), as evidenced by histopatho-
logical and immunological studies, the potential involvement of
infectious agents, and genetic influences to disease suscept-
ibility. Thus, this system is considered to be a relevant infectious
animal model for MS (Dal Canto et al., 1996; Kim et al., 2000).
However, the mechanism of TMEV-IDD is not well understood.
Many previous studies have suggested that the CD4+ T cell
response is pathogenic in susceptible SJL mice (Gerety et al.,
1994; Pope et al., 1996; Yauch and Kim, 1994; Yauch et al.,
1998). However, virus-specific CD4+ Tcells may also be able to
confer protection depending upon the timing of their presence
and/or genetic background (Johnson et al., 1999; Karls et al.,
2002; Mohindru et al., 2006; Murray et al., 1998b; Njenga et al.,
1996). It is suggested that CD8+ Tcells are primarily involved in
viral clearance and protection from the development of
demyelinating disease (Fiette et al., 1993; Lyman et al., 2004;
Pullen et al., 1993; Rodriguez et al., 1990, 1993). However, the
role of CD8+ T cells in the pathogenesis of demyelination in
susceptible mice remains unclear (Begolka et al., 2001; Murray
et al., 1998a; Palma and Kim, 2001). The role of antibodies to
TMEV has also been previously investigated and found to be
protective, despite the presence of high levels of such antibodies
in clinically affected mice (Fujinami et al., 1989; Kang et al.,
2005; Rodriguez et al., 1990; Rossi et al., 1991; Yahikozawa et
al., 1997). The major epitopes recognized by CD4+ T cells
(VP1233–250, VP274–86, VP324–37), CD8
+ T cells (VP3159–166,
VP3173–181, VP111–20), and several linear epitopes recognized
by B cells (A1A, A1C, A2B, A3A) in the CNS and periphery of
TMEV-infected susceptible SJL/J mice (Inoue et al., 1994; Kang
et al., 2002; Kim et al., 2000; Oleszak et al., 2004) have been
identified on the capsid proteins of TMEV.
In this study, we compared the efficacy of protection from
TMEV-induced demyelinating disease following oral and
peritoneal administration of intact live virus in order to under-
stand the underlying mechanisms of protection and patho-
genesis. Our results indicate that susceptible SJL mice orally
pre-exposed to TMEV, but not intraperitoneally, prior to intra-
cerebral infection clear viral persistence in the CNS and become
resistant to developing demyelinating disease. However, a
prolonged period after oral administration is necessary for
effective protection. Orally vaccinated mice displayed markedly
elevated levels of antibody response to TMEV in the serum and
showed increased early infiltration of B cells producing anti-
TMEV antibody into the CNS. Thus, the humoral immune
response appears to play an important role in oral immuniza-
tion-induced protection against TMEV-induced demyelinating
disease.Results
A prolonged time period is required after oral immunization to
protect from TMEV-IDD
In preliminary studies, we examined whether infection of
susceptible SJL/J mice via routes other than intracerebral
inoculation can also lead to the development of demyelinating
disease. None of the mice infected either intraperitoneally or
perorally with TMEV (up to 1×107 PFU tested) developed
clinical signs of demyelination during 150 d post-infection,
whereas 100% of mice infected intracerebrally showed clinical
signs at 60 days (data not shown). To assess the time required
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nistration of live TMEV, age-matched SJL/J mice, which were
perorally pre-exposed to 1×107 PFU live TMEV for 30 days,
45 days, or 51 days, were intracerebrally infected with 1×106
PFU TMEV (Fig. 1). Mice immunized perorally developed
clinical symptoms of demyelinating disease indistinguishable
from untreated control mice. In addition, the difference in
disease frequency between these groups was not statistically
significant (p=0.08), although the onset of disease appeared to
be delayed and the severity reduced. The results clearly indicate
that significant protection is not provided at 30 days after oral
administration (pN0.05); at least 45 days appear to be required
for significant protection (pb0.01) from developing demyeli-
nating disease following intracerebral infection. Induction time
of protection was not shortened by repeated oral administration
or by increased viral dose (not shown). These data suggest that a
prolonged time period is necessary to develop fully protective
immunity following oral infection.
Effective protection is induced following oral, but not
peritoneal, infection
To compare the relative efficacy for protection by the same
virus given via different routes, 1×107 PFU live virus was
administered either perorally or intraperitoneally at 45 days
prior to intracerebral infection with 1×106 PFU TMEV (Fig.
2). The results clearly indicate that intraperitoneal exposure toFig. 2. Protection from TMEV-IDD by oral, but not intraperitoneal, immunizatio
administered with 1×107 PFU intact BeAn at 45 days prior to intracerebral infect
immunization resulted in a significantly lower incidence of TMEV-IDD compared t
among the experimental groups are significant based on ANOVATukey–Kramer mul
intraperitoneally (IP) immunized groups; ***pb0.001, NONE vs. perorally (PO) im
(brains and spinal cords) of these groups (n=3–4) were assessed by plaque assay at 3
infection were significantly lower in PO immunized mice compared to those of IP ithe virus prior to intracerebral infection confers significant
protection (pb0.0001) against the development of clinical
demyelinating disease (Fig. 2A). However, the same dose of
virus given perorally induced much more effective protection
(p=0.01) compared to that administered intraperitoneally. In
contrast, exacerbation was seen after intracerebral adminis-
tration prior to CNS viral infection instead of protection (data
not shown). These data clearly demonstrate that oral
administration of live TMEV induces superior protective
immunity against demyelinating disease subsequent to intra-
cerebral infection with the virus, compared to intraperitoneal
delivery.
Viral persistence is drastically reduced in the CNS of orally
vaccinated mice
In order to correlate the protection induced by prior
exposure to virus with viral persistence following intracerebral
infection, levels of replicating TMEV in the CNS of mice
untreated and pre-exposed to the virus either orally or
peritoneally were compared (Fig. 2B). It is interesting to note
that higher virus levels were observed in the CNS (brains and
spinal cords) of intraperitoneally vaccinated mice at 3 days
post intracerebral infection compared to untreated mice.
Similarly, viral levels of orally vaccinated mice were
significantly higher (pb0.001) compared to untreated control
mice. However, viral levels in the CNS of orally vaccinatedn. Female SJL/J mice (n=10 each group) were perorally or intraperitoneally
ion. Untreated mice were intracerebrally infected as a control group. (A) Oral
o intraperitoneally immunized mice or the untreated control group. Differences
tiple comparison test between days 39 and 95. **pb0.01, untreated (NONE) vs.
munized groups; *pb0.05, IP vs. PO. (B) Viral persistence levels in the CNS
and 27 days post CNS viral infection. TMEV levels at both 3 and 27 days post-
mmunized or unimmunized mice. *pb0.05; **pb0.01; and ***pb0.001.
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peritoneally vaccinated mice. Any plaque-forming viral titers
were detectable in the CNS of either intraperitoneally-infected
or perorally-infected mice at 45 dpi prior to intracerebral-
infection (not shown). It is not clear at this time why
administration of live virus orally or peritoneally prior to
intracerebral infection elevates the initial viral load in the
CNS. Perhaps free TMEV or cells harboring persistent TMEV
in the periphery of these mice may have rapidly migrated to
the CNS. Alternatively, preexisting immune responses in the
periphery may have activated glial cells to enhance initial viral
replication in the CNS. Nevertheless, initial levels of virus in
the CNS (3 days post-infection) were not correlated to
subsequent disease susceptibility, as control mice without
pre-exposure to the virus showed the lowest levels of virus at
this time point, yet developed the highest incidence of disease
(Fig. 2B). In contrast to viral levels seen immediately (3 days)
after intracerebral infection, viral levels in peritoneally treated
mice were significantly (p=0.02) reduced at 27 days post-
infection compared to those of untreated control mice. Orally
administered mice showed further reductions of viral persis-
tence both in the brain (p=0.04) and spinal cord (pb0.0001)
compared to those seen in peritoneally exposed mice. There-
fore, prolonged viral replication in the CNS of intracerebrally
infected mice that were previously exposed orally, but not
peritoneally, is severely restricted. The viral persistence level
of mice orally preexposed to TMEV is consistent with the
most effective protection by the treatment against the
development of TMEV-IDD (Fig. 2A).
Levels of anti-viral T cell responses in the periphery do not
correlate with protection
To examine whether differential levels of T cell responses
to viral determinants are induced between orally vaccinated
and intraperitoneally vaccinated mice, levels of splenic T cell
proliferation responses to viral antigens were assessed at
various time points after the administration of live TMEV
(Fig. 3). Two weeks (15 days) after the administration of live
virus, orally vaccinated mice exhibited slightly higher levels
of T cell proliferative responses. However, by the time of
intracerebral infection (45 days post-immunization), response
levels in this group were significantly lower compared to
those in intraperitoneally received mice (Fig. 3A). Some of
our results indicated that there were detectable levels of
antibodies in intraperitoneally immunized mice at 47 days
post-immunization and small but increased levels of antibody
titer following intracerebral infection. However, these levels
were consistently lower than those in orally immunized mice.
Only marginal differences were detected thereafter between
mice that received the virus intraperitoneally or perorally. In
order to compare levels of proinflammatory Th1 cell
responses, IFNγ levels produced by CD4+ T cells were
assessed (Fig. 3B). Levels of IFNγ produced by CD4+ T cells
during the early stage of CNS viral infection (45–52 days)
were also marginally reduced in mice pre-exposed to the virus
orally compared to those in mice pre-exposed intraperi-toneally. Similarly, virus-specific IFNγ-producing CD8+ T
cell levels in the periphery were increased in both orally and
peritoneally pre-exposed mice compared to untreated mice
(Fig. 3C). However, no such significant difference was de-
tected between orally and peritoneally immunized mice.
These results suggest that the level of peripheral T cell res-
ponses to viral determinants induced by immunization with
live virus does not correlate with the level of protection from
demyelinating disease.
Levels of anti-viral T cell responses in the CNS are higher in
orally pre-exposed mice
To further correlate immune responses to TMEV with the
efficacy of protection induced by live virus immunizations,
levels of T cell responses to viral antigens in the CNS, which is
the site of viral persistence and demyelination, were determined
by flow cytometry (Fig. 4A). The infiltration levels of overall
CD4+ and CD8+ T cells to the CNS of vaccinated mice were
significantly increased at 3 days post intracerebral infection.
However, these levels became similar to those of untreated mice
after 6 days post-infection. Further ELISPOT results determin-
ing the levels of IFNγ-producing T cells upon stimulation with
individual epitopes were consistent with the above flow
cytometric analysis (Fig. 4B). Levels of IFNγ-producing
CD4+ and CD8+ T cells specific for viral determinants in the
CNS of orally vaccinated mice were consistently higher than
those of intraperitoneally vaccinated mice throughout the course
of viral infection. These results suggest that oral administration
of live virus is capable of effectively enhancing the level of
virus-specific T cells, in particular the level of virus-specific
CD8+ T cells, in the CNS following intracerebral infection of
TMEV (Fig. 4), in contrast to those in the periphery (Fig. 3).
Antibody levels in serum are higher in mice immunized
perorally than intra-peritoneally
To examine whether higher levels of antibodies produced
following oral immunization are responsible for effective
prevention from the development of demyelinating disease,
TMEV-specific antibody levels in mice vaccinated via different
routes were assessed during the course of viral infection (Fig.
5). It is interesting to note that only orally vaccinated mice
showed a significant level of anti-TMEV antibodies in the
serum at the time of intracerebral TMEV infection (47 days
post-immunization) and during early (7 days) CNS viral
infection (Fig. 5A). However, the level of antibodies in
intraperitoneally immunized mice gradually increased to the
level of orally vaccinated mice at 22 days post CNS infection
and thereafter; such an increase also followed in control mice
that were not vaccinated. In vitro virus-neutralizing levels of
sera correlated with anti-TMEV antibody levels, but did not
correlate with disease levels (not shown), as previously shown
(Inoue et al., 1994). Both IgG1 and IgG2a isotypes of anti-
TMEV antibodies were produced, suggesting the lack of Th
type preference for antibody production (Fig. 5B). No
difference in the levels of anti-TMEV antibodies (IgA and
Fig. 3. Peripheral T cell responses to TMEVantigens in mice vaccinated via different routes. (A) Proliferative responses of splenic T cells to TMEVantigens in mice
orally or intraperitoneally vaccinated with live TMEV (n=3). Splenocytes from mice at days 15/−30 days, 45/0 days, 52/+22 days, or 115/+70 days (post-
immunization/intracerebral infection, respectively) were cultured for 4 days in the presence of UV-inactivated TMEVor synthetic peptides bearing the predominant
CD4+ Tcell epitopes (VP1233–250, VP2 74–86, and VP324–37). (B) IFNγ-producing splenic CD4
+ T cells in response to TMEV capsid epitopes determined by ELISPOT
assays. (C) IFNγ-producing CD8+ T cells in response to TMEVepitopes (VP111–20, VP3159–166, and VP3173–181) determined by ELISPOTassays. NS, not significant;
*pb0.05; **pb0.01; and ***pb0.001.
189B.-S. Kang et al. / Virology 366 (2007) 185–196IgG) was observed in the saliva of these mice at the time of
intracerebral infection, although oral administration initially
induced a higher level of these antibodies (Fig. 5C). These
results suggest that the presence of a high level of serum anti-
TMEV antibodies at the early stage of intracerebral infection
correlates with effective protection from demyelinating disease.More TMEV-specific B cells are initially present in the CNS of
orally immunized mice
To further correlate the level of antibodies elevated in
vaccinated mice at the early stage of CNS viral infection with
the efficacy of protection against TMEV-IDD, levels of CD19+
Fig. 4. Levels of T cells specific to TMEV antigens in the CNS of mice vaccinated via different routes. (A) Flow cytometric analyses of T cells among the CNS
mononuclear cells from vaccinated or untreated mice at 3, 6, and 27 days post intracerebral TMEV infection. The proportion of IFNγ-producing cells in response to the
mixture of CD4+ T cell epitope peptides and CD8+ T cell epitope peptides was determined by flow cytometry following intracellular cytokine staining. One
representative of three separate experiments with similar results is shown here. (B) The assessment of IFNγ-producing T cells infiltrating the CNS of vaccinated mice
in response to individual TMEV epitope peptides by ELISPOT assay at 6 and 14 days post CNS TMEV infection. The statistic values represent the significance
between vaccinated and non-vaccinated mice and the values inside the parentheses represent the difference between orally vaccinated and peritoneally vaccinated
mice. *pb0.05; **pb0.01; and ***pb0.001. When the values of three CD8+ T cell epitopes (VP111–20, VP3159–166, and VP3173–181) were pooled, ***, NONE vs. IP;
***, NONE vs. PO; **, IP vs. PO at 6 days post-infection, and *, NONE vs. IP; ***, NONE vs. PO; *, IP vs. PO at 14 days post-infection.
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determined (Fig. 6). Levels of B cells infiltrating the CNS were
relatively higher in orally vaccinated mice compared to those in
peritoneally vaccinated or untreated mice during the early stage
(3–6 days) of CNS viral infection (Fig. 6A). Levels of anti-
TMEV antibody-producing B cells in the CNS and periphery
were further determined by ELISPOT assay using UV-TMEV
coated plates (Fig. 6B). The results clearly indicate that
significantly higher levels of anti-TMEV antibody-producing
B cells are present in the CNS and periphery during the earlyphase (3–14 days) of viral infection in orally vaccinated mice
compared to intraperitoneally vaccinated mice. Therefore, both
the level of serum antibodies and the number of antibody-
producing B cells in the CNS correlate well with the efficacy of
protection, consistent again with the possibility that the primary
mechanism of protection from TMEV-IDD following oral
immunization is via the production of virus-specific antibodies.
Antibodies to a predominant VP1 epitope in orally vaccinated
mice are elevated
To further analyze the nature of antibodies at the beginning
of viral infection in mice vaccinated via different routes, the
reactivity of antibodies to previously characterized predomi-
nant, linear antibody epitopes (Inoue et al., 1994) was assessed
(Fig. 7). Susceptible SJL mice intracerebrally infected with
TMEV were shown to strongly recognize the A1C epitope
(VP1262–276) as compared to resistant BALB/c or C57BL/6
mice (Inoue et al., 1994). The antibody population reactive to
this viral epitope was predominant in orally vaccinated mice,
but not in peritoneally vaccinated mice, during the early stage
(within 7 days) of viral infection (Fig. 7A). This pattern is
consistent with our previous results demonstrating that
preimmunization with either VP1 protein or A1C-epitope
peptide can protect mice against subsequent intracerebral
TMEV infection (Yahikozawa et al., 1997). However, antibody
levels to this epitope become predominant during late infection
regardless of the route of immunization, as previously shown in
mice with clinical symptoms of demyelination (Yahikozawa et
al., 1997). It is unclear why mice displaying elevated levels of
such antibodies during late infection are not protected against
TMEV-IDD. In order to determine the potential role of
antibodies to this epitope during the late stage of viral
infection, pooled serum from mice immunized with A1C-
KLH was transfused to naive SJL/J mice before or after
intracerebral TMEV infection. The disease courses of these
groups were then compared to each other and to an untreated
mouse group (Fig. 7B). The results clearly indicate that the
presence of antibodies during the beginning of viral infection to
the CNS, but not during late infection, is protective against
TMEV-IDD. In fact, the presence of such antibodies after the
establishment of viral persistence appears to exacerbate the
disease. These results are consistent with previous reportsFig. 5. Antibody levels to TMEV in mice vaccinated orally and peritoneally.
(A) Mice were bled at 17/−30 days, 47/0 days, 54/+7 days, 69/+22 days,
117/+70 days, or 159/+112 days post-immunization followed by intracerebral
infection, respectively. Antibody levels to TMEV in pooled serum (n=5) were
analyzed by ELISA. Sera from orally vaccinated mice show markedly higher
levels of antibodies to TMEV compared to those from peritoneally vaccinated
mice (pb0.001) in the early stages of viral infection (47/0 and 54/+7 days
post-immunization/infection). (B) The isotype determination of anti-TMEV
antibody in pooled sera from mice at 47/0 days post-immunization/infection.
Serum IgG subclasses (IgG1 and IgG2a) were determined by ELISA. (C)
Antibody titers detected in saliva reactive to UV-inactivated TMEV. Saliva
washes were collected from mice at 17/−30 days and 54/7 days post-
immunization/infection. Samples were pooled and analyzed by ELISA. Total
IgA levels were not different between the groups (data not shown).
Fig. 7. Epitope reactivity and the potential role of antibodies in virus-infected
mice. (A) Reactivity of anti-TMEV antibodies to linear epitopes in sera from
mice (n=4) at 47/0 days and 103/+56 days post-immunization/infection.
Antibodies to A1C (VP1262–276) and A3A (VP324–37) were relatively higher in
orally vaccinated mice at 47/0 days compared to peritoneally vaccinated mice;
the level of antibodies to A1C selectively increased after viral infection
regardless of immunization. (B) Effect of transfusion of antibodies specific to
the A1C epitope on the development of demyelinating disease. Naive SJL/J
mice were repeatedly immunized with A1C-KLH and the serum was transfused
into SJL/J mice (n=10/group) before (−5, 0, and 5 days) or after (12, 19, and
25 days) intracerebral viral infection. Differences between groups that received
serum antibodies before and after viral infection (pb0.002) and between the
group that received antibodies after viral infection and the group that did not
receive any antibodies (p=0.01) were very significant based on a paired, two-
tailed Student's t-test between 33 and 61 days post-infection. Also, the
difference between the group that received antibodies prior to viral infection and
the group that did not receive antibodies was significant (pb0.03) based on a
paired, two-tailed Student's t-test between 47 and 75 days post-infection.
Similar results were observed in a separate additional experiment.
Fig. 6. TMEV-specific B cells in the CNS and periphery during the course of
viral infection. (A) Flow cytometric analysis of B cells infiltrating the CNS of
mice (47 days prior to viral infection) at 50/3, 53/6, and 74/27 days post-
immunization/infection, respectively. The percentages of CD19+ cells in the
CNS MNC from non-vaccinated, orally and peritoneally vaccinated mice were
determined at 3, 6, and 27 days post-infection. (B) Enumeration of anti-TMEV
antibody-producing cells in the CNS and periphery during the course of viral
infection. *pb0.05; **pb0.01; and ***pb0.001. A representative of three
separate experiments is shown here.
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protective, although clinically affected mice with demyelinat-
ing disease display high levels of such antibodies, which are
capable of neutralizing viral infection/replication in vitro (Kang
et al., 2005; Mohindru et al., 2006; Yahikozawa et al., 1997;
Inoue et al., 1994).
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Despite the fact that oral vaccination is widely used to
protect against many viral infections (Cox et al., 2004; Fekadu
et al., 1996; Foxwell et al., 2006; Ramakrishna et al., 1999;
Sabin, 1985), very few systematic studies have been conducted
to examine the time required to obtain maximal protection and
the type of immune responses involved in this protection. In this
study, we investigated the potential protective effects of pre-
exposure to live virus through non-pathogenic routes, i.e.
intraperitoneally and perorally, against TMEV-induced demye-
linating disease. This virus is widely spread via fecal–oral
routes among the wild type mouse population without apparent
disease (Lipton et al., 2001; Thompson et al., 1951; and not
shown). Therefore, such studies may provide important
information regarding the relationship between the pathogen-
esis of inflammatory demyelination upon access to the CNS and
previous exposure to the virus via oral infection. Our results
indicate that susceptible SJL/J mice pre-exposed to live TMEV
perorally, but not intraperitoneally, are resistant against TMEV-
induced demyelinating disease (Figs. 1 and 2). It is interesting to
note that a prolonged time period (N45 days) is necessary to
acquire effective protection following oral immunization. The
mechanisms involved in such delayed protection are unclear.
However, a similar delayed period is also required to produce
significant levels of antibodies in the serum (Fig. 5), which
apparently provide important protective immunity (Kang et al.,
2005; Rodriguez et al., 1990). In addition, it was previously
shown that intraperitoneal immunization with attenuated
TMEV significantly reduce viral load in the CNS through the
production of neutralizing antibodies (Kurtz et al., 1995). Thus,
it is most likely that the presence of a high level of anti-viral
antibodies prior to CNS viral infection is responsible for the
protection provided by oral immunization (Fig. 7). Since the
majority of picornaviruses, including TMEV, are enteric viruses
that spread through the fecal–oral route, a prolonged stimula-
tion of immune responses by viruses residing in the mucosal
system may provide an effective generation of such protective
immunity. However, TMEV introduced intraperitoneally may
be cleared more rapidly and/or may be ineffective at inducing
vigorous antibody responses.
The roles of antibodies in controlling viral persistence and
protecting mice against TMEV-induced demyelinating disease
are not yet completely understood. It is generally accepted
that the antibody response to various viruses is protective by
either neutralizing viral infection or inhibiting viral replication
(Burton, 2002; Griffin et al., 1997). In addition, several
neurotropic viruses, including mouse hepatitis virus, require
the continuous presence of antibodies in order to effectively
control viral persistence, as a lack of antibodies results in
viral recrudesces (Ramakrishna et al., 2003). However,
antibodies specific to viral determinants do not play a signi-
ficant role in either the protection or pathogenesis of CNS
diseases in some viral systems (Burton, 2002; Schneider-
Schaulies et al., 2003). Therefore, it is not yet clear whether
antibodies play protective and/or pathogenic roles in certain
virus-induced diseases.The potential role of antibodies specific for TMEV in viral
clearance and protection from TMEV-IDD has also been
previously investigated. B cells producing anti-TMEV anti-
bodies have been identified in the demyelinating lesion (Cash et
al., 1989). Some antibodies to TMEVappear to cross-react with
autoantigens on the myelin and oligodendrocytes, suggesting a
pathogenic role of such antibodies (Yamada et al., 1990).
Furthermore, elevated antibody responses are seen in the CNS
as well as in the periphery of susceptible mice undergoing
demyelinating disease compared to healthy TMEV-infected
resistant mice (Inoue et al., 1994). These results suggest a
potential pathogenic role of antibodies to TMEV. However, the
removal of B cells by treatment with anti-IgM antibody
exacerbates disease (Kurtz et al., 1995; Rodriguez et al.,
1990). A marked decrease in the number of virus-infected cells
in the CNS of susceptible mice was also observed after passive
transfer of sera from virus-infected resistant donors (Borrow et
al., 1993; Rossi et al., 1991). Furthermore, susceptible SJL mice
preimmunized with isolated capsid proteins or linear antibody
epitopes conjugated to carrier molecules are resistant to TMEV-
induced demyelination (Yahikozawa et al., 1997). Recently, we
demonstrated that antibody response is critical in protecting
mice against TMEV-induced disease, especially when the level
of CD8+ T cell response is low (Kang et al., 2005). These
findings are consistent with our present study indicating that the
presence of antibodies specific for TMEV prior to and/or during
the initial stage of viral infection following oral immunization
(Fig. 5) or serum transfusion (Fig. 7) provides powerful
protection against virally induced demyelinating disease.
However, such antibodies during chronic viral infection may
not be protective and/or may even be pathogenic (Fig. 7). Taken
together, these results indicate that the time of availability of a
sufficient level of anti-viral antibodies is critical for effective
protection.
The correlation between the level of peripheral T cell
responses and the efficacy of protection from TMEV-induced
demyelinating disease is less clear. It was previously shown that
CD4+ T cells raise antibody levels, which are critical for
protection during the early stage of viral infection (Borrow et
al., 1993). Peripheral T cell responses in both CD4+ and CD8+ T
cell populations in either peritoneally or orally vaccinated mice
showed significant increases compared to untreated mice.
However, differences in peripheral T cell responses between
the vaccinated groups were not consistent with their levels of
protection (Fig. 3). If anything, these levels were often
somewhat lower in orally vaccinated mice compared to those
in peritoneally vaccinated mice. It is unclear at this time why
there is a discrepancy between the level of peripheral T cell
responses and the efficacy of protection, which correlates with
the level of anti-TMEV antibody in the blood. It is conceivable
that virus-specific T cells may have been sequestered at the
mucosal site in orally vaccinated mice, leading to a lower T cell
level in the periphery compared to peritoneally vaccinated mice.
This possibility is consistent with the higher levels of virus-
specific antibodies found in the circulation and the number of T
cells present in the CNS during the beginning of intracerebral
infection (Figs. 4 and 5). Therefore, it is most likely that both
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against TMEV-induced demyelinating disease during the early
stage of viral infection, as was recently demonstrated for
TMEV-specific CD8+ Tcells (Lyman et al., 2004), CD4+ Tcells
(Mohindru et al., 2006) and antibodies (Kang et al., 2005).
The level of CNS-infiltrating virus-specific immune cells
showed a clearer correlation to the efficacy of vaccine-induced
protection. Levels of both anti-viral CD4+ and CD8+ T cell
responses in the CNS are the highest in orally vaccinated mice,
followed by peritoneally vaccinated and then untreated mice
during the early stage of viral infection (Fig. 4). In particular,
levels of CD8+ T cells in the CNS of orally vaccinated mice are
significantly higher. Similarly, levels of CNS-infiltrating B cells
specific for TMEV are also highest in orally vaccinated mice
among the groups during the early stage of CNS viral infection
(Fig. 6). These results strongly suggest that the levels of virus-
specific immune cells present in the CNS during early infection
are critically important in controlling viral load and its
consequent viral persistence in the CNS. The significant
elevation of immune responses in the CNS during early viral
infection appears to be most effectively achieved following oral
immunization, resulting in superior protection against TMEV-
induced demyelinating disease. Therefore, the widely spread
infection of TMEV in wild mice may function as a powerful
means to provide strong protection against this virus, which
causes devastating disease when it accesses the CNS.
Materials and methods
Mice
Female SJL/J mice, 4–6 weeks old, were purchased from the
Charles River Laboratories (Charles River, MA) via the
National Cancer Institute. Mice were subsequently housed in
the Northwestern University animal care facility. All mouse
procedures approved by the Northwestern University Animal
Care and Use Committee were used in this study.
Virus
The BeAn strain of TMEV was expanded in BHK cell
monolayers in DMEM supplemented with 7% donor calf serum.
Cell lysates with known PFU were used as viral stock for animal
experiments. Partially purified virus was prepared following
centrifugation through 30% sucrose as previously described
(Yauch et al., 1998) and used for in vitro assays. Viral titer was
determined by the standard plaque assay on BHK cells.
Ultraviolet inactivation of virus (UV–TV) was achieved by
exposure to a UV light source for 2 h as previously described
(Palma et al., 1999).
Immunization and infection with virus
To vaccinate susceptible SJL/J mice with live TMEV,
1×106–1×107 PFU in 200 μl DMEM were administered
either intraperitoneally or perorally (back of oral cavity) via
fitted plastic tubing to avoid tissue abrasion starting from 5weeks of age. After described time periods, live virus was
intracerebrally inoculated to induce demyelinating disease.
Demyelinating disease was induced by injection of 1×106 PFU
TMEV in 30 μl into the right cerebral hemisphere of female
SJL/J mice after anesthetization. Intracerebral injection with
1×106 PFU consistently induces chronic gait abnormalities and
neurologic signs in greater than 90% of SJL/J mice. Clinical
symptoms of disease were assessed weekly on the following
grading scale: grade 0=no clinical signs; grade 1=mild
waddling gait; grade 2=moderate waddling gait and hindlimb
paresis; grade 3=severe hindlimb paralysis; grade 4=severe
hindlimb paralysis and loss of righting reflex; grade 5=death.
Analysis of TMEV-specific Abs
Abs specific for viral epitopes were measured by an
adaptation of the indirect ELISA previously described (Inoue
et al., 1994). Briefly, either 0.3 μg of UV-inactivated TMEV
virus or 0.1 μg of synthetic peptides conjugated to BSA was
used to coat microtiter plates and then the plates were blocked
with 1% Blotto. Two-fold serial dilutions of sera in triplicates
starting from 1:100 dilution were added, washed, and then
allowed to react with alkaline phosphatase-conjugated goat anti-
mouse secondary antibody. For assessment of IgG isotypes,
polyclonal goat antibodies to mouse IgG1 and IgG2a (Southern
Biotech) also recognizing IgG2ab (or IgG2c) of C57BL/6 and
SJL/J strains were used (Martin et al., 1998). The enzyme
reaction was developed using p-nitrophenyl phosphate and
measured colorimetrically by an ELISA reader at 405 nm.
Measurement of T cell proliferation
T cell proliferation was determined using splenocytes from
control or virus-infected SJL/J mice. Single cell suspensions of
splenocytes (5×105/well) in RPMI-medium supplemented with
5×10−5 M 2-ME and 0.5% normal syngeneic mouse serum
were cultured for 72 h in triplicate in the presence of 1 or 10 μM
peptides or 12.5 μg/ml UV-inactivated TMEV. Approximately
18 h after the addition of 1 μCi/well of [3H]-TdR (Amersham,
Arlington Heights, IL), cells were harvested and [3H]-TdR
incorporation was determined in a liquid scintillation counter.
Results are expressed as Δcpm (mean cpm of experimental
stimulated cultures after subtraction of the background count
with PBS)±SEM from triplicate cultures.
Preparation of CNS mononuclear cells (MNC)
Sterile HBSS (30 ml) was used to perfuse the tissues through
the left ventricle. Brains and spinal cords were then removed,
forced through a steel screen, and the resulting cell suspensions
were incubated at 37 °C for 45 min in 250 μg/ml collagenase
type 4 (Worthington Biochemical Corp., Lakewood, NJ). A
continuous 100% percoll gradient (Pharmacia, Piscataway, NJ)
in the bottom 1/3 of the gradient after centrifugation at
27,000×g for 30 min was used to enrich CNS infiltrating
lymphocytes. All antibodies used for flow cytometry were
purchased from BD Biosciences (San Diego, CA).
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To measure IFN-γ producing cells, ELISPOT plates
(Millipore, Bedford, MA) were pre-coated with 1–5 μg/ml of
anti-IFN-γ antibody in 0.05 M carbonate buffer, pH 9.6. Plates
were incubated with 2×104 CNS mononuclear cells plus 1×106
irradiated (3000 rad) syngeneic spleen cells or 1×106
splenocytes from infected mice alone in 200 μl HL-1 medium
(Bio-Whittaker, Walkersville, MD) for 18 h at 37 °C in the
presence of 2 μM peptide. After washing, plates were incubated
with biotin-conjugated anti-IFN-γ antibody (Endogen, Boston,
MA) overnight. To assess anti-TMEVantibody producing cells,
CNS MNC were similarly cultured in ELISPOT plates pre-
coated with UV-TMEV (5 μg/ml) for 18 h followed by
treatment with biotin-conjugated rabbit anti-mouse IgG. Spots
were developed after incubation with streptavidin-HRP for 3 h
using 3-amino-9-ethyl-carbazole (Sigma, St. Louis, MO) in
0.05 M sodium acetate buffer (Targoni and Lehmann, 1998).
Flow cytometry
Fc receptors on CNS MNC were blocked using 50 μl of
2.4G2 hybridoma (ATCC) supernatant. Cells were then stained
with APC-conjugated CD8 (Clone Ly-2) and PE-conjugated
anti-CD4 (clone L3T4) antibodies. To analyze B cells, cells
were stained with PE-conjugated anti-CD19 (clone 1D3)
antibody.
Statistical analyses
The significance (two-tailed p value) of the differences
between experimental animal groups with various treatments
and the control group was analyzed based on the unpaired,
Student's t-test by using the InStat Program (GraphPAD
Software, San Diego, CA). Differences in disease course
between experimental groups were determined by paired two-
tailed t-test analysis, with the Welch correction. Values of
pb0.05 were considered significant.
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